IGF-1 DES vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
IGF-1 DESGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- IGF-1 DES (also written DES(1-3)IGF-1) is a truncated form of IGF-1 missing the first three amino acids of the N-terminus. This structural change dramatically reduces its affinity for IGF binding proteins (IGFBPs), meaning a far greater fraction remains in its free, active form. IGF-1 DES is estimated to be 10x more potent than standard IGF-1 LR3 at the receptor level locally, making it particularly effective for site-specific muscle growth when injected intramuscularly.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- ~20–30 minutes (very short — designed for local action)
- ~5 days
- Admin Route
- IM, SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 20–50 mcg per injection site
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- Once daily, post-workout
- Once weekly, subcutaneous
- Key Benefits
- Estimated 10x greater potency at the receptor vs IGF-1 LR3 locally
- Minimal IGFBP binding — nearly all active upon injection
- Highly localized muscle growth effect when injected intramuscularly
- Activates satellite cells for muscle fiber hyperplasia potential
- Synergistic with GH peptides in post-workout anabolic protocols
- Shorter half-life reduces systemic exposure vs IGF-1 LR3
- Useful for site-specific muscle development
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Hypoglycemia (most significant risk — especially post-workout)
- Localized muscle swelling at injection site
- Potential for jaw/organ growth (acromegalic effects) with prolonged high-dose use
- Carpal tunnel syndrome with high doses
- +1 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —